The relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics and cognitive performance has been investigated.
Since amyloid beta (Aβ) peptides are the main component of the amyloid plaques found in Alzheimer patients' brains, changes in levels of Aβ in blood plasma may provide a biomarker for detecting increased risk or early diagnosis of disease.
Scientists at the University of New South Wales (Sydney, Australia) examined 126 age-matched cognitively normal controls, 89 individuals with amnestic mild cognitive impairment (aMCI,) from the Center for Healthy Brain Aging (CHeBA) Sydney Memory & Aging Study (Sydney MAS), as well as 39 individuals with Alzheimer's disease (AD) recruited from a specialty clinic.
Read more: Plasma Levels Investigated as Alzheimer's Disease Biomarkers
 |
| A diagram of the formation of amyloid plaques in the brain of an Alzheimer brain compared with a normal brain |
Source: Junji Takano
